North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence ...

D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie, in collaboration with REGENXBIO Inc., is ...

Patients with challenging diabetic macular edema may achieve anatomical gains and extended dosing intervals with bispecific faricimab.

Background/aims To evaluate efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with wet age-related macular degeneration (wAMD) from the VIEW 2 trial.